Literature DB >> 30859232

[Concepts in geriatric uro-oncology].

A Manseck1, S Manseck2, C Körner2.   

Abstract

Uro-oncology is not only concerned with treatment methods themselves but also with therapeutic objectives and decision-making concepts involving algorithms. We discuss whether the latter is applicable to all patients groups or needs to be adapted in order to be suitable for elderly and frail patients with regard to their lifestyle and living situation as well as their altered physiology.

Entities:  

Keywords:  Activities of daily living; Geriatric assessment; Prostate cancer; Renal cell carcinoma; Transition cell carcinoma

Mesh：

Year:  2019        PMID： 30859232     DOI： 10.1007/s00120-019-0892-7

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  21 in total

1.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

Authors:  Thomas E Hutson; Vladimir Lesovoy; Salman Al-Shukri; Viktor P Stus; Oleg N Lipatov; Angel H Bair; Brad Rosbrook; Connie Chen; Sinil Kim; Nicholas J Vogelzang
Journal:  Lancet Oncol       Date:  2013-10-25       Impact factor: 41.316

2.  Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Authors:  Daniel L Suzman; Mario A Eisenberger
Journal:  Eur Urol       Date:  2013-10-16       Impact factor: 20.096

3.  Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.

Authors:  Axel Heidenreich; Sergio Bracarda; Malcolm Mason; Haluk Ozen; Lisa Sengelov; Inge Van Oort; Christos Papandreou; Sophie Fossa; Simon Hitier; Miguel Angel Climent
Journal:  Eur J Cancer       Date:  2014-01-31       Impact factor: 9.162

4.  Management of cancer in the older person: a practical approach.

Authors:  L Balducci; M Extermann
Journal:  Oncologist       Date:  2000

5.  Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.

Authors:  Peter F A Mulders; Arturo Molina; Michael Marberger; Fred Saad; Celestia S Higano; Kim N Chi; Jinhui Li; Thian Kheoh; Christopher M Haqq; Karim Fizazi
Journal:  Eur Urol       Date:  2013-09-20       Impact factor: 20.096

6.  The changing prevalence of comorbidity across the age spectrum.

Authors:  Jay F Piccirillo; Anna Vlahiotis; Laurel B Barrett; Kellie L Flood; Edward L Spitznagel; Ewout W Steyerberg
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-28       Impact factor: 6.312

Review 7.  The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.

Authors:  Joaquim Bellmunt; Sylvie Négrier; Bernard Escudier; Ahmad Awada; Matti Aapro
Journal:  Crit Rev Oncol Hematol       Date:  2008-09-05       Impact factor: 6.312

Review 8.  Optimal management of renal cell carcinoma in the elderly: a review.

Authors:  Amandine Quivy; Amaury Daste; Asma Harbaoui; Sophie Duc; Jean-Christophe Bernhard; Marine Gross-Goupil; Alain Ravaud
Journal:  Clin Interv Aging       Date:  2013-04-19       Impact factor: 4.458

Review 9.  Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.

Authors:  Jean-Pierre Droz; Lodovico Balducci; Michel Bolla; Mark Emberton; John M Fitzpatrick; Steven Joniau; Michael W Kattan; Silvio Monfardini; Judd W Moul; Arash Naeim; Hendrik van Poppel; Fred Saad; Cora N Sternberg
Journal:  BJU Int       Date:  2010-03-25       Impact factor: 5.588

10.  Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study.

Authors:  Pierre Soubeyran; Carine Bellera; Jean Goyard; Damien Heitz; Hervé Curé; Hubert Rousselot; Gilles Albrand; Véronique Servent; Olivier Saint Jean; Isabelle van Praagh; Jean-Emmanuel Kurtz; Stéphane Périn; Jean-Luc Verhaeghe; Catherine Terret; Christophe Desauw; Véronique Girre; Cécile Mertens; Simone Mathoulin-Pélissier; Muriel Rainfray
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.